In study results presented at the American Pain Society’s 31st Annual Scientific Meeting, researchers revealed that the spray is effective following a 90-day double-blind, placebo-controlled patient study. Of the 163 patients who completed the study, less than a third reported side effects associated with using the fentanyl sublingual spray, compared to 45 percent reporting side effects with previous medications for breakthrough cancer pain.
The most common side effects reported among patients were nausea (13 percent), vomiting (12 percent) and somnolence (10 percent).
Related Articles on Pain Management:
Distraction Reduces Perceived Pain
Study: Nucynta Effective Pain Reliever for Diabetic Peripheral Neuropathy
Study Targets Effective Adolescent Migraine Relief
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
